These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 4352112)

  • 1. Nasopharyngeal carcinoma and Epstein-Barr virus. II. Clinical course and the anti-VCA antibody.
    Lynn T; Tu S; Hirayama T; Kawamura A
    Jpn J Exp Med; 1973 Apr; 43(2):135-44. PubMed ID: 4352112
    [No Abstract]   [Full Text] [Related]  

  • 2. Nasopharyngeal carcinoma and Epstein-Barr virus. I. Factors related to the anti-VCA antibody.
    Lynn T; Tu S; Hirayama T; Kawamura A
    Jpn J Exp Med; 1973 Apr; 43(2):121-33. PubMed ID: 4352111
    [No Abstract]   [Full Text] [Related]  

  • 3. Epstein-Barr virus-associated antibodies and serum biochemistry in nasopharyngeal carcinoma.
    Lynn TC; Hsieh RP; Chuang CY; Huang SC; Hsieh T; Tu SM
    Laryngoscope; 1984 Nov; 94(11 Pt 1):1485-8. PubMed ID: 6092804
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of anti-Epstein-Barr virus antibodies in nasopharyngeal carcinoma (NPC).
    Liu MT; Yeh CY
    Radiat Med; 1998; 16(2):113-7. PubMed ID: 9650898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The diagnosis of nasopharyngeal carcinoma (author's transl)].
    Arnold W; Nakazima A; Wang YB; Vosteen KH; Brunner H; Göbel U
    HNO; 1980 Aug; 28(8):247-60. PubMed ID: 6254933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to Epstein-Barr virus-related antigens in nasopharyngeal carcinoma. Comparison of active cases with long-term survivors.
    Henle W; Ho HC; Henle G; Kwan HC
    J Natl Cancer Inst; 1973 Aug; 51(2):361-9. PubMed ID: 4358130
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognosis of nasopharyngeal carcinoma by Epstein-Barr virus antibody titer.
    Lynn T; Hsu M; Hsieh T; Tu S
    Arch Otolaryngol; 1977 Mar; 103(3):128-32. PubMed ID: 189741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nasopharyngeal carcinoma and Epstein-Barr virus. III. The detection of anti-nuclear antibodies.
    Lynn TC; Hsu MM; Hsieh T; Tu SM; Hamajima K
    Jpn J Exp Med; 1976 Oct; 46(5):289-95. PubMed ID: 189106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies of the Epstein-Barr herpesvirus relationship with Hodgkin's disease and the use of virus immunological markers in differential diagnostics of nasopharyngeal carcinoma.
    Mazurenko NP; Gurtsevich VE; Stepina VN; Plakhov IV
    Arch Geschwulstforsch; 1983; 53(3):253-9. PubMed ID: 6311138
    [No Abstract]   [Full Text] [Related]  

  • 11. Anti-Epstein Barr virus antibody in nasopharyngeal carcinoma.
    Hsu MM; Chiou JF; McCabe BF
    Ann Otol Rhinol Laryngol; 1974; 83(1):19-25. PubMed ID: 4359674
    [No Abstract]   [Full Text] [Related]  

  • 12. Epstein-Barr virus is not associated with head and neck neoplasms other than nasopharyngeal carcinoma.
    Kottaridis SD; Goula I; Kiparissiadis P
    Neoplasma; 1982; 29(3):327-31. PubMed ID: 6290911
    [No Abstract]   [Full Text] [Related]  

  • 13. Nasopharyngeal carcinoma and Epstein-Barr virus--associated serologic markers.
    Tam JS; Murray HG
    Ear Nose Throat J; 1990 Apr; 69(4):261-7. PubMed ID: 2161732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Further studies on antibodies to early antigens induced by Epstein-Barr virus in nasopharyngeal carcinoma patients.
    Ida S; Hinuma Y; Chu CT; Chiou JF; Lai JG
    Gan; 1973 Dec; 64(6):545-53. PubMed ID: 4360581
    [No Abstract]   [Full Text] [Related]  

  • 15. Epstein-Barr virus-related serology in nasopharyngeal carcinoma and controls.
    Henle W; Henle G; Ho JH
    IARC Sci Publ (1971); 1978; (20):427-37. PubMed ID: 215525
    [No Abstract]   [Full Text] [Related]  

  • 16. [Value of anti-Epstein-Barr antibody detection in the diagnosis and management of undifferentiated carcinoma of the nasopharynx].
    Mazeron MC
    Bull Cancer Radiother; 1996; 83(1):3-7. PubMed ID: 8679277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Malaria antibody levels in patients with nasopharyngeal carcinoma.
    Yadav M; Prasad U
    Southeast Asian J Trop Med Public Health; 1984 Jun; 15(2):234-7. PubMed ID: 6095462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antibody response against the Epstein-Barr virus-coded nuclear antigen2 (EBNA2) in nasopharyngeal carcinoma.
    Chatani M; Teshima T; Inoue T; Yoshino K; Ikegami N; Hirai K; Shimakage M
    Laryngoscope; 1991 Jun; 101(6 Pt 1):626-9. PubMed ID: 1645832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Epstein-Barr virus--a clinically relevant feature of nasopharyngeal carcinoma? (author's transl)].
    Wilmes E; Wolf H; Deinhardt F; Naumann HH
    Laryngol Rhinol Otol (Stuttg); 1981 Jan; 60(1):4-6. PubMed ID: 6261051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
    Cao SM; Min HQ; Gao JS; Hong MH; Xiao XB; Zhang CQ; Liu XD; Zhang AL; Guo X
    Ai Zheng; 2003 Mar; 22(3):302-6. PubMed ID: 12654192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.